Altman Advisors Inc. Buys 19,309 Shares of Novo Nordisk A/S (NYSE:NVO)

Altman Advisors Inc. raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 121.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,260 shares of the company's stock after buying an additional 19,309 shares during the quarter. Novo Nordisk A/S comprises approximately 1.0% of Altman Advisors Inc.'s holdings, making the stock its 29th largest position. Altman Advisors Inc.'s holdings in Novo Nordisk A/S were worth $2,343,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Cullen Frost Bankers Inc. grew its stake in shares of Novo Nordisk A/S by 1.2% in the 1st quarter. Cullen Frost Bankers Inc. now owns 116,829 shares of the company's stock worth $8,113,000 after buying an additional 1,387 shares in the last quarter. Kornitzer Capital Management Inc. KS grew its position in Novo Nordisk A/S by 0.3% in the first quarter. Kornitzer Capital Management Inc. KS now owns 155,858 shares of the company's stock worth $10,823,000 after acquiring an additional 396 shares in the last quarter. PAX Financial Group LLC increased its stake in Novo Nordisk A/S by 87.4% during the first quarter. PAX Financial Group LLC now owns 10,119 shares of the company's stock worth $703,000 after acquiring an additional 4,719 shares during the last quarter. Mosaic Family Wealth Partners LLC increased its stake in Novo Nordisk A/S by 8.7% during the first quarter. Mosaic Family Wealth Partners LLC now owns 3,198 shares of the company's stock worth $222,000 after acquiring an additional 257 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in Novo Nordisk A/S by 7.1% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 78,984 shares of the company's stock valued at $5,485,000 after purchasing an additional 5,265 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 2.5%

Shares of NYSE NVO traded down $1.67 during trading hours on Thursday, reaching $65.37. The stock had a trading volume of 8,082,685 shares, compared to its average volume of 7,365,953. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $139.74. The firm has a market cap of $291.86 billion, a price-to-earnings ratio of 19.35, a P/E/G ratio of 1.29 and a beta of 0.64. The business's fifty day moving average price is $70.36 and its two-hundred day moving average price is $74.67. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Wall Street Zen raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Finally, BMO Capital Markets restated a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.